MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.[1] The aim of this project was to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA[2] and utilising the beta-emitting isotope rhenium-188 (188Re). The outcomes from the research project - which included a pre-clinical and first-in-human evaluation - have been published in the latest issue of the Journal of Nuclear Medicine.[3] The project has resulted in new intellectual property and a translational data package that may be used to advance this compound into a Phase I clinical trial. Telix is now progressing discussions regarding the further development of the compound with the goal of spinning-out this program into an innovative new compan
MELBOURNE, Australia, Feb. 14, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted
/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted.
/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted.